All News

With a likely rate cut by the Federal Reserve this week, investors could rotate aggressively back to the sector.

Multi-region clinical trials can provide for varied results, but may not paint a full picture for a specific population.

Results from the ADvocate 1, ADvocate 2, and ADhere clinical trials found that patients treated with Ebglyss 38% of patients with moderate-to-severe atopic dermatitis achieved clear or almost-clear skin after 16 weeks of treatment.

Ocrevus Zunovo is the first and only twice-yearly, 10-minute subcutaneous injection for treating both relapsing multiple sclerosis and primary-progressive multiple sclerosis.

The Apple AirPods 2 will include software enabling hearing aid services.

The app will work alongside prescription drug treatment Flexilev.

The profitability of biopharma drug launches in the US will remain in decline until manufacturers reimagine their approach with payers

Landmark results from the Phase III PURPOSE 2 trial found that lenacapavir demonstrated 89% greater efficacy than Truvada in preventing HIV infections.

Subcutaneous Tecentriq Hybreza will provide patients and physicians increased flexibility for administration of the immunotherapy across approved indications for Tecentriq, including non–small cell lung cancer, small cell lung cancer, and hepatocellular carcinoma.

These services will help alleviate the impact of contraceptive deserts in the state.

Dupixent displayed a nearly 50% reduction in itch and urticaria activity scores in patients with chronic spontaneous urticaria.

Tremfya is the first and only fully-human, dual-acting monoclonal antibody targeting IL-23 and CD64 to be approved for the treatment of moderately to severely active ulcerative colitis.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.

Users of the platform will have access to Kyzatrex.

In this interview, Melissa Krebs,Ph.D., CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.

Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.

The company will begin investigating the effectiveness of TCP008 for the highly infectious disease.

AI is a tool to make drug discovery cheaper, faster, and better — not a replacement for human ingenuity.

This is the second biosimilar that the company is offering to its customers at this price.

Filspari is considered the first non-immunosuppressive treatment to significantly slow kidney function decline in adults with IgA nephropathy.

Results of the FENopta study found that after one year of treatment, 96% of patients experienced no relapses of multiple sclerosis, with an annualized relapse rate of just 0.04.

The device is part of the growing home health monitoring trend.

Customers will be able to file one claim across multiple products from the company.

Results from the MATINEE trial found that Nucala led to a statistically significant and clinically meaningful reduction in moderate/severe exacerbations of chronic obstructive pulmonary disease compared to placebo over 104 weeks.

Texas Biomed announced that research shows that a certain monoclonal antibody treatment could treat all variants of COVID-19, including past, present, and future strains.

Boruzu is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma.

Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.